Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin.
Implementing this research evidence requires not only an understanding of the trials'results and of the changes that they imply for clinicians'treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes.
Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment.
This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials'results.
These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.
Mots-clés Pascal : Fibrillation auriculaire, Traitement, Chimiothérapie, Anticoagulant, Warfarine, Critère décision, Choix, Malade, Service hospitalier, Approvisionnement, Organisation, Surveillance, Homme, Appareil circulatoire pathologie, Cardiopathie, Trouble rythme cardiaque, Trouble excitabilité
Mots-clés Pascal anglais : Atrial fibrillation, Treatment, Chemotherapy, Anticoagulant, Warfarin, Decision criterion, Choice, Patient, Hospital ward, Supply, Organization, Surveillance, Human, Cardiovascular disease, Heart disease, Arrhythmia, Excitability disorder
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0041135
Code Inist : 002B02F02. Création : 01/03/1996.